drugset / Trial / NCT00989014

Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea

NCT00989014

Phase 2 Completed 122 enrolled Galderma R&D
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, parallel-group, vehicle-controlled, dose-finding study to investigate the pharmacodynamics and the safety of three dosages of CD07805/47 topical gel (0.07%, 0.18%, and 0.50%), after a single application in subjects with a clinical diagnosis of stable moderate to severe erythematotelangiectatic rosacea. Subjects will be randomized in a 1:1:1:1 ratio to receive either one of three CD07805/47 topical gel concentrations (0.07%, 0.18%, or 0.50%) or Vehicle Gel. All subjects will be treated with a single application (once daily dosing for one day) of study medication.

Timeline

Start
2009-09
Primary completion
2009-11
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.07 % Topical
Subject Brimonidine Small molecule 0.18 % Topical
Subject Brimonidine Small molecule 0.5 % Topical

Indications